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background:  Recent clinical studies have shown contradictory results about the effect of erythropoietin (EPO) on reperfusion injury in 
myocardial infarction. In this study, we investigated whether the intracoronary administration of long acting EPO, darbepoetin-α, at the time 
of reperfusion would reduce infarct size or pathologic left ventricular (LV) remodeling in patients with ST-segment elevation myocardial 
infarction (STEMI).
methods:  We randomly assigned 80 STEMI patients (onset < 12 hr) to the EPO and placebo group. Each group was treated with 
intracoronary bolus (300 ug) darbepoetin-α or saline via over-the-wire balloon at the time of first balloon inflation. Cardiac enzymes (CK-
MB and TnI) were measured for 48 hours after reperfusion. 57 patients completed cardiac magnetic resonance (CMR) at discharge and 
after 4 months. Primary endpoint was the infarct size estimated by peak cardiac enzymes. Secondary endpoints were LV remodeling index 
{[LV end diastolic volume (LVEDV) at 4 month - baseline LVEDV] / baseline LVEDV X 100} and the incidence of pathologic LV remodeling 
(LV remodeling index > 20%), the change in LV ejection fraction, LVEDV, infarct size assessed by CMR and major adverse cardiovascular 
events (cardiac death, myocardial infarction, rehospitalization or cerebral infarction) during 4 months.
Results:  The peak level of cardiac enzyme were not significantly different between EPO and placebo group (CK-MB; 299.2 ± 189.2 vs 
285.8 ± 217.8, respectively, p=0.77: TnI; 158.0 ± 132.7 vs 143.8 ± 123.8, respectively, p=0.62). At 4 months, the LV remodeling index was 
not statistically different between the 2 groups (EPO -0.16 ± 14.43 % vs placebo 4.80 ± 16.28 %, p=0.24) and the incidence of pathologic 
LV remodeling also did not differ (EPO 8.0 % vs placebo 6.7 %, p=0.62). There were no significant differences between the 2 groups with 
respect to LV ejection fraction, LVEDV and infarct size at baseline and 4 months. The major adverse cardiovascular events occurred in 5 
patients (12.8 %) in the EPO and 3 patients (7.5 %) in the placebo (p=0.48).
conclusion:  Intracoronary darbepoetin-α therapy at the time of reperfusion did not reduce infarct size or pathologic LV remodeling in 
patients with STEMI.
